Formycon AG
↗Planegg-Martinsried, Germany
Formycon AG is a leading independent developer of high-quality biosimilars, which are follow-on products of biopharmaceutical medicines. The company focuses on key therapeutic areas including ophthalmology, immunology, and immuno-oncology, covering the entire value chain from technical development and clinical trials to regulatory approval and commercialization support.
Headquartered in Martinsried near Munich, Formycon operates as a pure-play biosimilar specialist. It has successfully transitioned from a development-focused organization to a commercially oriented company with several approved products in major global markets like the US and EU, typically leveraging strategic partnerships for global distribution.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:€70M - €115M
Founded:2012
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:ATHOS (Major Shareholder), Wendel, Institutional and Private Investors
STOCK
Exchange:Frankfurt Stock Exchange (XETRA)
Ticker:FYB
Market Cap:~€1.0B
PIPELINE
Stage:Commercial
Lead Drug Stage:Approved / Marketed
Modalities:mAbs, Fusion proteins, Biosimilars
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 3: 3
FDA Approvals:3
EMA Approvals:3
CORPORATE STRUCTURE
Subsidiaries:Formycon Project 201 GmbH, Formycon Project 202 GmbH
Key Partnerships:Fresenius Kabi (Commercialization partner for FYB202/Otulfi), Sandoz (Partnership for FYB201 in Europe), Zydus Lifesciences (Licensing for FYB206 in US/Canada), Teva (Commercialization for FYB201/FYB203 in specific regions), Klinge Biopharma (Commercialization rights for FYB203)
COMPETITION
Position:Leader
Competitors:Samsung Bioepis, Amgen, Celltrion, Biocon Biologics, Alvotech
LEADERSHIP
Key Executives:
Dr. Stefan Glombitza - CEO
Enno Spillner - CFO
Dr. Andreas Seidl - CSO
Nicola Mikulcik - CBO
Scientific Founders:Dr. Carsten Brockmeyer, Dr. Thomas Schlegl
Board Members:Wolfgang Essler (Chairman), Colin Bond, Klaus Röhrig, Nicholas Haggar, Dr. Graham Dixon
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Formycon AG. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.